Cart is empty Approximately 30% of the global population is affected by metabolic-associated fatty liver disease (MASLD), a condition that previously lacked targeted treatments. Researchers have now identified a genetic factor that exacerbates the disease, and remarkably, the FDA-approved drug that most effectively targets this factor is vitamin B3.
Leave A Comment